Spigel, D.R., Hainsworth, J.D., Simons, L., Meng, C., Burris III, H.A., Yardley, D.A., Grapski, R., Schreeder, M., Mallidi, P.V. and Greco, F.A. (2007) Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Netwo-
rk. Journal of Thoracic Oncology, 2, 854-861. http://dx.doi.org/10.1097/JTO.0b013e31814617b7

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.